DiaSorin Molecular has announced the expansion of its menu of molecular reagents with the introduction of a Pneumocystis jirovecii primer pair for use in laboratory-developed molecular tests. This analyte-specific reagent (ASR) can be used for the amplification and detection of the Pneumocystis jirovecii mtLSU gene with a CFR610- and BHQ-2-labeled probe and forward and reverse primers. This is DiaSorin’s first fungal infectious disease target.
The new primer pair joins DiaSorin’s menu of more than 60 molecular reagents that can be used to detect bacterial and viral targets in addition to human genetic mutations. The primer pairs are classified as analyte-specific reagents, which are used by high-complexity laboratories to develop their own lab-developed tests (LDTs).
“This new primer pair is the result of our ongoing work to develop and deliver a robust menu of molecular products,” said Michelle Tabb, vice president of research and development for DiaSorin Molecular. “With greater access to commercially developed molecular reagents, diagnostic labs are better able to customize tests that meet their unique patient needs.”
Clinical research, forensic and anti-doping toxicology laboratories facing the challenges of analyzing increasing numbers of analytes in biological matrices, can now easily and rapidly optimize their liquid chromatography-mass spectrometry (LC-MS) methods for targeted screening and quantification.
ENPICOM, an innovative bioinformatics software engineering company specialized in decoding the immune system, announced that the Princess Margaret Cancer Centre of the University Health Network (UHN) has purchased a subscription to ENPICOM’s data analysis platform.
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the results of a patient study that successfully demonstrates the use of exhaled limonene as a breath biomarker to measure liver function and stage liver disease.